542. Use of Bamlanivimab in Cancer Patients with Mild-to-Moderate COVID-19
Patricia Brock(The University of Texas MD Anderson Cancer Center), Issam Raad(Missouri Department of Agriculture), Ray Hachem(The University of Texas MD Anderson Cancer Center), Daniel J. Coussirat(The University of Texas MD Anderson Cancer Center), Maria Susan Gaeta(The University of Texas MD Anderson Cancer Center), Hiba Dagher(The University of Texas MD Anderson Cancer Center), Alexandre Malek(Louisiana State University Health Sciences Center Shreveport), Adriana H. Wechsler(The University of Texas MD Anderson Cancer Center), Tami N. Johnson(The University of Texas MD Anderson Cancer Center), Demis N. Lipe(The University of Texas MD Anderson Cancer Center), Anne‐Marie Chaftari(The University of Texas MD Anderson Cancer Center), Ying Jiang(The University of Texas MD Anderson Cancer Center), Samuel L Aitken(The University of Texas MD Anderson Cancer Center), Patrick Chaftari(The University of Texas MD Anderson Cancer Center)
Cited by 8
Related Papers
Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.6k
Guidelines for the Management of Intravascular Catheter-Related Infections
|Clinical Infectious Diseases|2001|1.5k
A Comparison of Two Antimicrobial-Impregnated Central Venous Catheters
|New England Journal of Medicine|1999|806
Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial
|Clinical Infectious Diseases|2006|752
Comparative Activities of Daptomycin, Linezolid, and Tigecycline against Catheter-Related Methicillin-Resistant <i>Staphylococcus</i> Bacteremic Isolates Embedded in Biofilm
|Antimicrobial Agents and Chemotherapy|2007|347